🚨T-1
#ASCO24
@ASCO
! 💪🏼
All set to showcase exciting
#NSCLC
#LCSM
research!
#ASCOLung24
⬇️ Current updated management algorithm for NSCLC, with addition of
1️⃣ Periop Pembrolizumab
2️⃣ Adjuvant Alectinib
3️⃣ Osi/Chemo for EGFRm
4️⃣ Ami/Chemo for EGFR Ex20ins
5️⃣ Repotrectenib ROS1
Thrilled to announce my next adventure as a Thoracic/Phase 1 Medical Oncologist with
@ONealCancerUAB
!
Heartfelt gratitude for the support of my family, colleagues, and mentors. 🙏🏻🙏🏻
Y’all! Let’s connect at
@ASCO
#ASCO23
to discuss partnerships, collaborations and trials in
LAURA Ph 3: Osimertinib vs Placebo
#ASCO24
@ASCO
➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️
➡️ 24-mo PFS: 65% vs 13% 📈
➡️ 81% received osi at progression 💊, Good!
➡️AE discontinuation**: 13% vs 5% ⚠️
Can't wait for
@RamalingamMD
's presentation today! 🎤
#ASCO24
@OncoAlert
Data
LCRF has announced 3 research grant awards funded by Daiichi Sankyo and AstraZeneca, focused on further developing the understanding of the proposed mechanism of action of antibody drug conjugates (ADCs).
#LungCancer
@ADesaiMD
@NSethakorn
Carl Gay, MD, PhD
Out now! ⚡️
@NatRevClinOncol
"
#circulating
tumour DNA 🧬 — looking beyond the blood 🩸" discuss
ctDNA from non-blood sources, focusing on urine, cerebrospinal fluid, and pleural or peritoneal
fluid, and complementary role to blood ctDNA analysis
@Oncoalert
@isliquidbiopsy
“Missing the target in cancer therapy”
@NatureCancer
discusses how for many lethal malignancies, the majority of clinical trials are conducted with patients who do not have biomarkers and hence they miss the target.
@OncoAlert
@jacobadashek
@Dr_R_Kurzrock
Announcing the 2024 ASCO Annual Meeting Featured Voices! Follow along for a range of expert insights & join the discussion using the official hashtag:
#ASCO24
⤵️
📢 T-2
#ASCO24
@ASCO
! set to showcase some
#SCLC
#LCSM
research, hopefully pushing boundaries in this field!
➡️Improving outcomes for
#SCLC
is a critical need!
👇Current management algorithm for SCLC, with addition of
#Tarlatamab
in 2024! ✔️
➡️And some interesting studies
📢
#ASCO23
@ASCO
set to showcase some innovative
#SCLC
#LCSM
research, hopefully pushing boundaries in this field! 👩🔬🎗️
🫁 Improving outcomes for
#SCLC
#LCSM
is a critical need!
🧭 Current management algorithm for SCLC 👇🏼
➡️ And some interesting
#SCLC
studies being presented
Excellent review of "Modes of Regulated Cell Death in
#Cancer
"
@CD_AACR
@OncoAlert
describes key RCD modalities apoptosis, entosis, necroptosis, pyroptosis, and ferroptosis.
@OncoAlert
Thank you
@JAMAOnc
for ✍️ my thoughts on similarities between ♟and 🦀!
As an oncologist the mantras of chess have been unexpectedly relatable, but I am hoping to use my learnings against a more formidable opponent! 🦀
@MayoHemeOnc
@HemOncFellows
Updated
@NCCN
v5.2023
#lcsm
are out!
🗝️ Category 1️⃣ for Perioperative Pembrolizumab from KN 671!
🙏 Thrilled to join the esteemed guideline panel, a pivotal resource during my training and ongoing practice. Eager to contribute to this vital resource for many!
@OncoAlert
"Biased Evaluation in Cancer Drug Trials—How Use of
#PFS
as the Primary End Point Can Mislead"
@JAMAOnc
by
@ian_tannock
and Dr. Booth is a must read for
@HemOncFellows
! Excellent piece on how PFS benefits may be spurious with no OS benefit!
@OncoAlert
I'm thrilled and grateful to represent
@UABMedicine
@UABNews
and join amazing colleagues on the
#Communications
#Committee
of
@IASLC
(International Association for the Study of Lung Cancer) 🎉🙌
Proud to be part of this fantastic association committed to studying and eradicating
Curious Question for
#lcsm
experts:
#Osimertinib
costs $914/month, taking it for 3 years will be 395,223$ for a single patient with Stage IB-IIIA EGFRm NSCLC after resection to provide them DFS 89 v 53%, benefit and with no current
#OS
data- will it be sustainable?
@VPrasadMDMPH
🎉 Early 🎄🎁
@IASLC
! Delighted to share that I've been accepted into
@IASLC
Academy 2024! Eager to embark on this enriching journey, connect with peers, mentors, and friends. Grateful for the opportunity! 🙏
@LungCancerRx
with 💪🏼 representation there!
@esinghimd
@FawziAbuRous
🎉Excited to be an
#ASCO23
Featured voice
@ASCO
with stellar colleagues, and friends!
I will be tweeting about
#LCSM
, phase 1 trials and interesting drugs in the horizon for all things
#solidoncology
!
👇🏼 List of
#LCSM
abstracts of interest!
Follow these 🌟🌟
#OncTwitter
📣 Announcing the
#ASCO23
Featured Voices! 🎉 Follow on Twitter, Instagram and/or LinkedIn for a range of expert insights and join the conversation using the official hashtag:
#ASCO23
👉
#ASCO22
#Plenary
Dr. Yoshino presents "Panitumumab (PAN)+ mFOLFOX6 versus bevacizumab (BEV)+ mFOLFOX6 in 1st-line left-sided RASwt
#crcsm
: PARADIGM trial!
➡️mOS: 37.9 mos vs 34.3 for Left-sided
➡️mOS: 36.2 vs 31.3 for overall
RR/R0 resection rates 🔼
@OncoAlert
@HemOncFellows
Do you agree?
Amivantamab + Chemo is new 1L SOC for EGFR ex20ins adv NSCLC
@nicogirardcurie
et al. at
#ESMO23
with PAPILLON study
Amivantamab + CT:
⬆️ PFS (HR, 0.40); ⬆️ all subgroups
⬆️ ORR (73 vs 47%)
⬆️ DOR (9.7 vs 4.4 mo)
#NSCLCBrief
@LealTiciana
7 days to go for
@ASCO
#ASCO23
!
Plan your meeting and be ready to get lost in
#data
and McCormick! Well, one of them we can prepare for!
👀 the floorplan for McCormick at
#ASCO23
! 📍🗺️ Plus, check out where all the exciting exhibit booths will be! 🎪🔬
Big thanks to
@montypal
Analysis of
#ctDNA
before/after
#Rx
with curative intent of patients with early-stage
#NSCLC
> detection of ctDNA with personalized assays can inform patient prognosis and guide Rx
@Annals_Oncology
@OncoAlert
So excited to see Dr. Karen Kelly
@IASLC
discuss the advances in
#LCSM
at the Early Career Workshop, and utilize this image that me and
@MatthewHoMD
created! Kudos to the progress we have made, and really humbled to see our work being used
@OncoAlert
#WCLC22
@JackWestMD
🔔 Don't miss out!
Join me,
@AndreaAnampaG
@cissamathias
🙋♀️🙋♂️ at
#ASCO23
🏛️
➡️June 3 at 🕗 8 AM CST!
I'm truly honored 🎖️ to chair a session with these ✨ on
“How to navigate 🧭 the annual meeting 🗓️ effectively.” This is your golden chance 🌟 to maximize your
@ASCO
🚨 In
@isliquidbiopsy
journal
"Putting comprehensive 🧬 profiling of ctDNA to work"
We explore ctDNA's utility across 4 categories:
1️⃣ Established 💊 selection
2️⃣ Emerging
3️⃣ Incidental discovery of secondary genomic findings
4️⃣ Quantification
🎙️ Targeted Oncology is thrilled to announce the first episode of
#EmergingExperts
, a new podcast highlighting emerging talents in the oncology field, drops this Friday! In this episode,
@ADesaiMD
of
@ONealCancerUAB
shares his experiences and advice. Stay tuned!
"Transforming the landscape of early cancer detection using blood tests" excellent commentary by Dr. Liu
@MayoCancerCare
describing the tumour cell-free DNA (cfDNA), genomic technologies and machine learning in
#screening
!
@nature
@BrJCancer
@OncoAlert
Bittersweet memories
@MayoHemeOnc
on last clinic day! 🥲
So thankful and grateful to be part of this program and of the
#cancer
journey of my patients! 🙏🏻 Really blessed to be an oncologist.
@HemOncFellows
Among all accolades and academic achievements, these and many other
Out in
@JCO_ASCO
NECTIN4 Amplification predicts Enfortumab Vedotin response in Urothelial Cancer
#mUC
💊 96% response rate to EV therapy in amplified cases vs 32% in others (P < .001).
➡️Perhaps we need to look deeper than IHC for other ADCs too? 🤔
“
#COVID19
vaccination: the VOICE for patients with
#cancer
”
@NatureMedicine
describes the VOICE study (‘vaccination against COVID in cancer’) study of patients with solid malignancies undergoing active anticancer treatment.
@COVID19nCCC
@OncoAlert
@myESMO
#ESMO21
#Twitter
has been crazy! So much exciting data and potentially practice changing! Trying to keep up only via
#medtwitter
, this is so far I’ve gotten… what did I miss? Practice changing studies only, ones you will discuss with patients next week!
@OncoAlert